Global Prurigo Nodularis Therapeutics Market, by Product Type (Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 824.4 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The Prurigo nodularis therapeutics market is expected to witness rapid growth over the forecast period, owing to increasing research and development products.
On, 2018, Menlo Therapeutics Inc., announced the top line result from MTI-103 (ATOMIK), the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis (AD)
Global Prurigo Nodularis Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe such as U.S., Europe, and India has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors that has been majorly impacted by the pandemic.
The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient visits, among others.
Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities, thus causing disruption in supply chain of products.